[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355324-105":59,"doc-detail-355324-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","mov10-a-novel-immunotherapy-and-prognostic-biomarker-contributes-to-glioma-development-by-regulating-autophagy","MOV10, a novel immunotherapy and prognostic biomarker, contributes to glioma development by regulating autophagy","","MOV10 is investigated as a novel RNA helicase immunotherapy and prognostic biomarker in glioblastoma and broader glioma development. Elevated MOV10 expression is shown across GBM datasets and is strongly negatively associated with overall survival, confirmed by Cox regression as an independent risk factor. Functional enrichment links MOV10 to immune regulation and tumor progression. Experimental results indicate MOV10 knockdown reduces M2 macrophage migration and invasion, while MOV10 silencing suppresses proliferation and EMT-like processes and promotes apoptosis via autophagy modulation, supporting MOV10 as a therapeutic target.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/mov10-a-novel-immunotherapy-and-prognostic-biomarker-contributes-to-glioma-development-by-regulating-autophagy/355324/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/mov10-a-novel-immunotherapy-and-prognostic-biomarker-contributes-to-glioma-development-by-regulating-autophagy/355324.png","ImageObject",300,407,{"name":92,"@type":93},"Mia  ","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What role does MOV10 play in glioblastoma prognosis?","Question",{"text":112,"@type":113},"MOV10 expression is elevated in glioblastoma and is strongly negatively correlated with overall survival. Cox regression identifies MOV10 as an independent prognostic risk factor.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does MOV10 influence glioma immune microenvironment and immunotherapy relevance?",{"text":117,"@type":113},"MOV10 expression correlates with immune infiltration and immune checkpoint expression, and it is linked to responses to immunotherapy. The study also positions MOV10 in innate immune-related pathways affecting tumor immunity.",{"name":119,"@type":110,"acceptedAnswer":120},"What cellular mechanisms are affected when MOV10 is silenced?",{"text":121,"@type":113},"MOV10 knockdown suppresses glioblastoma cell proliferation, inhibits EMT-like processes, and promotes apoptosis. These effects are mediated through modulation of autophagy.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},355324,1790798352,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},687207024478,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nMOV10, a novel immunotherapy and prognostic biomarker, contributes to glioma development by regulating autophagy  \nFeiyu Wang1,4, Linlin Ruan1,2, Wenbin Yang2, Yueben Hu3, Yangzhong Guo1, Xuanxuan Xiong2,5, Dan Liu2,5, Qiaoli Lv1,4􀀍 & Shuhui Chen1􀀍  \nGlioblastoma (GBM) is a highly aggressive and lethal brain tumor, and despite conventional treatments, patient prognosis remains poor. Understanding the molecular mechanisms driving GBMand identifying potential therapeutic targets is critical. MOV10, an RNA helicase, is overexpressed in multiple cancers and is considered an oncogene. Our analysis of datasets from TCGA, GEO, and CGGA showed that MOV10 expression is elevated in GBM and strongly negatively correlated with overall survival (OS) . Cox regression confirmed MOV10 as an independent prognostic risk factor  \nfor GBM.Functional enrichment analysis revealed that MOV10 is involved in immune regulation and tumor progression pathways. We found that MOV10 expression is closely linked to immune infiltration, immune checkpoint expression, and responses to immunotherapy. Immunofluorescence and Transwell assays confirmed that MOV10 knockdown reduced M2 macrophage migration and invasion in GBM cells. Clinical analysis further validated MOV10 overexpression in GBM tissues.In vitro, MOV10 silencing suppressed GBM cell proliferation, inhibited EMT-like processes, and promoted apoptosis through autophagy modulation. Our findings suggest that MOV10 plays a crucial role inGBM progression and could be a promising molecular target for therapy.  \nKeywords Glioma, MOV10, Immune infiltration, Epithelial-mesenchymal transformation, Autophagy, Apoptosis  \nGliomas are the most common type of primary malignant tumor in the central nervous system, known for their high recurrence, disability, and mortality rates, as well as a low cure rate1. According to WHO, more than 11 million people are diagnosed with gliomas annually2. Gliomas are categorized into WHO grades I to IV, based on malignancy level3, with glioblastoma (GBM) being the most aggressive. GBM patients have a median survival time of just 8 months, with only 3% to 5% of them surviving more than 3 years4. The primary reasons for poor prognosis include treatment resistance and tumor recurrence after surgery. The exact mechanisms behind the aggressive growth of gliomas remain unclear5, making treatment particularly challenging. As a result, there is a pressing need to investigate the biological origins of gliomas, identify potential diagnostic and therapeutic targets, and develop new treatment strategies.  \nMoloneyleukemiavirus10 (MOV10) protein is a newly discovered factor with broad-spectrum antiretroviral potential. MOV10 proteins belong to RNA helicase superfamily 1 (SF-1)6,7. MOV10 can interact with AGO2 (Argonaute 2) and participate in the metabolism and translation of mRNA8. It is a component of the RNAinduced silencing complex (RISC)9. MOV10 is a new type of RNA binding protein (RBP) that is highly expressed in cancer cells and is considered to be an oncogene10. The expression of MOV10 protein is significantly increased in pancreatic cancer, and as an RBP protein, it improves the proliferation and invasive ability of pancreatic cancer cells11. Recent studies have shown that MOV10 can mediate the expression of miRNA-103a-3p (miRNA- 382-5p) by binding to circ-DICER1 and then affect the angiogenesis of glioma cells by regulating the PI3K/AKT  \n1Jiangxi Key Laboratory of oncology(2024SSY06041), JXHC Key Laboratory of Tumour Metastasis, Jiangxi Cancer Hospital & Institute, The Second Affiliated Hospital of Nanchang Medical College, Nanchang 330029, Jiangxi, P.R. China. 2School of Pharmacy, Nanchang University, Nanchang 330006, P. R. China. 3Department of Pharmacy, Nanchang People’s hospital(Nanchang Third hospital), Nanchang 330008, P. R. China. 4School of pharmacy, Yichun College, Yichun 336000, Jiangxi, China. 5","cbCaiv0gZj2myTe6","https://ap.wps.com/l/cbCaiv0gZj2myTe6","pdf",5760493,18,"English","# Background and Rationale\n## Glioblastoma prognosis and need for targets\n## MOV10 biology and immunology relevance\n# Study Approach\n## Public database analysis and survival modeling\n## Immune infiltration and immunotherapy linkage\n# Experimental Findings\n## Immune effects: M2 macrophages and migration/invasion\n## Cellular effects: proliferation, EMT-like processes, apoptosis\n## Mechanistic link to autophagy modulation\n# Implications","[{\"question\":\"What role does MOV10 play in glioblastoma prognosis?\",\"answer\":\"MOV10 expression is elevated in glioblastoma and is strongly negatively correlated with overall survival. Cox regression identifies MOV10 as an independent prognostic risk factor.\"},{\"question\":\"How does MOV10 influence glioma immune microenvironment and immunotherapy relevance?\",\"answer\":\"MOV10 expression correlates with immune infiltration and immune checkpoint expression, and it is linked to responses to immunotherapy. The study also positions MOV10 in innate immune-related pathways affecting tumor immunity.\"},{\"question\":\"What cellular mechanisms are affected when MOV10 is silenced?\",\"answer\":\"MOV10 knockdown suppresses glioblastoma cell proliferation, inhibits EMT-like processes, and promotes apoptosis. These effects are mediated through modulation of autophagy.\"}]","MOV10, a novel immunotherapy and prognostic biomarker, contributes to glioma development by regulating autophagy | PDF",1790117768,45,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/caba80e15d72f20dc2f96830210c49b8.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c2a31f04baaa87005645bb71939680c4.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b855267c18462e116281feee868c8648.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4cc4fec88fa4176b4692116457de2553.webp",980,1287]